Anti-MRSA Activities of Enterocins DD28 and DD93 and Evidences on Their Role in the Inhibition of Biofilm Formation

Atya, Ahmed K. Al; Belguesmia, Yanath; Châtaigné, Gabrielle; Ravallec, Rozenn; Vachée, Anne; Szunerits, Sabine; Boukherroub, Rabah; Drider, Djamel

doi:10.3389/fmicb.2016.00817

Cited by 60 publications

(50 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, it is worth mentioning that in this study we used enterocin without concentration or purification, we obtained promising results. Other studies have also reported the efficacy of unpurified enterocins against gram positive bacteria (CAMARGO et al 2016;AL ATYA et al 2016;ROCHA et al 2019).…”

Section: Resultsmentioning

confidence: 99%

Antimicrobial activity of enterocin obtained from Enterococcus durans on Shiga-like toxin-producing Escherichia coli

et al. 2019

View full text Add to dashboard Cite

Shiga-like toxin-producing Escherichia coli (STEC) is an important source of food contamination that presents risks to human health. Several industrial food processes eliminate this microorganism; however, these processes can alter the characteristics of the product. Alternative methods of preservation have been identified as an option to control these foodborne pathogens. The purpose of this study was to evaluate the action of bacteriocins produced by Enterococcus durans MF5 in STEC cells. Cell-free supernatant (CFS) containing enterocins from the MF5 isolate was tested over different time points (6, 18, and 24 h). Enterocins present in the crude CFS showed inhibition against STEC at all time points. In the investigation of cell integrity, using propidium iodide and fluorescence microscopy, considerable cell death was observed within 6 h of the cells being in contact with the enterocins, which was also observed at the 18 and 24 h time points. These results showed that the enterocins produced by the MF5 isolate have potential use in the control of STEC.

show abstract

Section: Resultsmentioning

confidence: 99%

Antimicrobial activity of enterocin obtained from Enterococcus durans on Shiga-like toxin-producing Escherichia coli

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This attribute has been observed for example, in enterocin E-760 (Line et al, 2008 ), enterocin P (Cintas et al, 1997 ), enterocin LR/6 (Kumar and Srivastava, 2010 ), and Enterocin AS-48 (Cobo Molinos et al, 2008 ). Besides, enterocins DD28 and DD93 have been reported to be active against MRSA and prevented film formation (Al Atya et al, 2016 ). Similarly, strains E. durans 61A (Hanchi et al, 2016 ), E. mundtii ST15 (De Kwaadsteniet et al, 2005 ), and ST4SA (Dicks et al, 2010 ) have showed a broad spectrum of activity including Gram-negative bacteria, an unusual property of bacteriocins produced by LABs.…”

Section: Advantages Of Enterococci and Their Bacteriocinsmentioning

confidence: 99%

The Genus Enterococcus: Between Probiotic Potential and Safety Concerns—An Update

et al. 2018

View full text Add to dashboard Cite

A considerable number of strains belonging to different species of Enterococcus are highly competitive due to their resistance to wide range of pH and temperature. Their competitiveness is also owed to their ability to produce bacteriocins recognized for their wide-range effectiveness on pathogenic and spoilage bacteria. Enterococcal bacteriocins have attracted great research interest as natural antimicrobial agents in the food industry, and as a potential drug candidate for replacing antibiotics in order to treat multiple drugs resistance pathogens. However, the prevalence of virulence factors and antibiotic-resistance genes and the ability to cause disease could compromise their application in food, human and animal health. From the current regulatory point of view, the genus Enterococcus is neither recommended for the QPS list nor have GRAS status. Although recent advances in molecular biology and the recommended methods for the safety evaluation of Enterococcus strains allowed the distinction between commensal and clinical clades, development of highly adapted methods and legislations are still required. In the present review, we evaluate some aspects of Enterococcus spp. related to their probiotic properties and safety concerns as well as the current and potential application in food systems and treatment of infections. The regulatory status of commensal Enterococcus candidates for food, feed, probiotic use, and recommended methods to assess and ensure their safety are also discussed.

show abstract

“…The enterocins were effective at inhibiting the formation of MRSA-1 biofilms on glass and SS surfaces when combined with the antibiotics kanamycin or erythromycin. 118 Finally, a novel circular sactibiotic, hyicin 4244, produced by Staphylococcus hyicus 4244, has been shown to exhibit anti-biofilm activity against fourteen Staphylococcus strains which were the causative agents of either bovine or human mastitis. 119 Significantly, the sactibiotic decreased the biofilm forming capacity of two of these strains as well as decreasing CFU (colony forming unit) counts.…”

Section: Anti-biofilm Activity Of Other Groups Of Bacteriocinsmentioning

confidence: 99%

Fighting biofilms with lantibiotics and other groups of bacteriocins

Mathur

Field

Rea

et al. 2018

npj Biofilms Microbiomes

168

112

View full text Add to dashboard Cite

Biofilms are sessile communities of bacteria typically embedded in an extracellular polymeric matrix. Bacterial cells embedded in biofilms are inherently recalcitrant to antimicrobials, compared to cells existing in a planktonic state, and are notoriously difficult to eradicate once formed. Avenues to tackle biofilms thus far have largely focussed on attempting to disrupt the initial stages of biofilm formation, including adhesion and maturation of the biofilm. Such an approach is advantageous as the concentrations required to inhibit formation of biofilms are generally much lower than removing a fully established biofilm. The crisis of antibiotic resistance in clinical settings worldwide has been further exacerbated by the ability of certain pathogenic bacteria to form biofilms. Perhaps the most notorious biofilm formers described from a clinical viewpoint have been methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Pseudomonas aeruginosa, Gardnerella vaginalis and Streptococcus mutans, the latter of which is found in oral biofilms. Due to the dearth of novel antibiotics in recent decades, compounded by the increasing rate of emergence of resistance amongst pathogens with a propensity for biofilm formation, solutions are urgently required to mitigate these crises. Bacteriocins are a class of antimicrobial peptides, which are ribosomally synthesised and often are more potent than their antibiotic counterparts. Here, we review a selection of studies conducted with bacteriocins with the ultimate objective of inhibiting biofilms. Overall, a deeper understanding of the precise means by which a biofilm forms on a substrate as well as insights into the mechanisms by which bacteriocins inhibit biofilms is warranted.

show abstract

Anti-MRSA Activities of Enterocins DD28 and DD93 and Evidences on Their Role in the Inhibition of Biofilm Formation

Cited by 60 publications

References 47 publications

Antimicrobial activity of enterocin obtained from Enterococcus durans on Shiga-like toxin-producing Escherichia coli

Antimicrobial activity of enterocin obtained from Enterococcus durans on Shiga-like toxin-producing Escherichia coli

The Genus Enterococcus: Between Probiotic Potential and Safety Concerns—An Update

Fighting biofilms with lantibiotics and other groups of bacteriocins

Contact Info

Product

Resources

About